Výsledky vyhledávání - "Mitsuyoshi, Tanishima"

Preliminary report: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult participants: a non-randomized, open-label phase 2/3 clinical study in Japan

Autor: Keishi Kido, Kayo Ibaragi, Mitsuyoshi Tanishima, Yosuke Muramoto, Shun Nakayama, Kohei Ata, Kenshi Hayashida, Hideki Nakamura, Yasuhiko Shinmura, Yoshiaki Oda, Masafumi Endo, Kengo Sonoda, Yuji Sasagawa, Yasuhiro Iwama, Kohji Ueda, Takayuki Matsumoto

BackgroundIn the prolonged COVID-19 pandemic, there remains a high need for the development of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine that can be used more safely and effectively to prevents the disease onset or severe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9d5f3f53454ad72617a56231d958e279
https://doi.org/10.1101/2022.10.27.22281603

Zobrazit plný text záznamu

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan

Autor: Mitsuyoshi Tanishima, Kayo Ibaraki, Keishi Kido, Shun Nakayama, Kohei Ata, Hideki Nakamura, Yasuhiko Shinmura, Masafumi Endo, Kengo Sonoda, Kohji Ueda, Yoshiaki Oda

BackgroundIn the current protracted COVID-19 pandemic, SARS-CoV-2 vaccines that have the ability to be used safely and to prevent onset or severe disease are still highly needed. A Phase 1/2 study was conducted in healthy adults and the elderly in Ja

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44208b33faf0e95f7305f6d5daaf1958
https://doi.org/10.1101/2022.06.28.22276794

Zobrazit plný text záznamu

Clinical phase II and III studies of an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66 ® cell culture platform

Autor: Masafumi Endo, Takeshi Naruse, Tetsuro Tanabe, Kohji Ueda, Tadashi Fukuda, Mitsuyoshi Tanishima, Kayo Ibaragi, Kenshi Hayashida, Yoichiro Kino

Publikováno v: Influenza and Other Respiratory Viruses. 14:551-563

Background We have developed an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66® cell culture platform (KD-295). Objectives In accordance with Japanese guidelines for development of pandemic prototype vaccines, the phase II study was cond

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d5a3b99b3dba1d5fc2b206f19391b9d2
https://doi.org/10.1111/irv.12755

Zobrazit plný text záznamu

Plný text ve formátu HTML

Clinical phase II and III studies of an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66

Autor: Masafumi, Endo, Mitsuyoshi, Tanishima, Kayo, Ibaragi, Kenshi, Hayashida, Tadashi, Fukuda, Tetsuro, Tanabe, Takeshi, Naruse, Yoichiro, Kino, Kohji, Ueda

Publikováno v: Influenza and Other Respiratory Viruses

Background We have developed an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66® cell culture platform (KD‐295). Objectives In accordance with Japanese guidelines for development of pandemic prototype vaccines, the phase II study was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::19789a22c30f1519768c0c8c8047dc3e
https://pubmed.ncbi.nlm.nih.gov/32579785

Zobrazit plný text záznamu

Akademický článek

Identification of optineurin as an interleukin-1 receptorassociated kinase 1-binding protein and its role in regulation of MyD88-dependent signaling.

Autor: Mitsuyoshi Tanishima¹, Shigeo Takashima², Arata Honda³, Daisuke Yasuda⁴, Takashi Tanikawa⁵, Satoshi Ishii⁴, Takashi Maru Yama^1,4 ta-maru@umin.ac.jp

Publikováno v: Journal of Biological Chemistry. 10/20/2017, Vol. 292 Issue 42, p17250-17257. 8p.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání